Gadoxetate Request in a Patient with Severe Renal Impairment
A 58-year-old man with type 2 diabetes and a 3.1 cm liver lesion seen on ultrasound is referred for liver MRI. His most recent eGFR is 28 mL/min/1.73 m², calculated two weeks ago; he takes metformin 1,000 mg twice daily and has no known contrast allergy. The referring clinician specifically requests gadoxetate disodium because 'it is better for liver lesions.' The patient is otherwise stable, not on dialysis, and has a functioning 22-gauge IV in the left antecubital fossa placed for bloodwork. The MRI slot is 60 minutes, and the radiologist is on site but in another building. The patient asks, 'Will this dye damage my kidneys?' and adds that his father needed dialysis. The requisition does not state whether the lesion is being staged or characterized. The department stocks gadobutrol, gadoterate meglumine, and gadoxetate.
1. How do you evaluate the contrast request, and which agent, if any, would you use?
Read the worked answer
The requested agent is not appropriate. Gadoxetate disodium is contraindicated in severe renal impairment, generally defined as eGFR below 30 mL/min/1.73 m², because of the risk of nephrogenic systemic fibrosis. His eGFR is 28, so do not give gadoxetate.
Next, clarify the clinical question with the radiologist: is the lesion being characterized, staged, or assessed for treatment response? If contrast is essential, a macrocyclic group II extracellular agent such as gadobutrol or gadoterate is preferred over linear agents, at the lowest dose likely to be diagnostic. Group II agents are associated with a much lower NSF risk, but caution is still required in severe renal impairment; this is a risk-benefit decision, not a routine order. If the question can be answered without contrast, perform a non-contrast liver MRI with T2, diffusion-weighted imaging, and pre-contrast T1 sequences.
Do not rely on hydration or dialysis to make a contraindicated agent safe. Document the eGFR value and date, the agent considered, the risk discussion, and the final radiologist decision.
2. What is the appropriate plan for metformin and renal-function follow-up?
Read the worked answer
Metformin itself is not a reason to withhold needed contrast, but it matters if contrast-associated acute kidney injury could lead to metformin accumulation and lactic acidosis. Because his eGFR is below 30, hold metformin at the time of contrast and reassess renal function at approximately 48 hours. Restart metformin only if renal function is stable and the clinical team agrees.
If no contrast is given, metformin does not need to be held for the MRI alone. If contrast is given, give the patient written instructions and notify the prescribing clinician. Counsel him about symptoms of lactic acidosis, such as unusual muscle pain, difficulty breathing, abdominal pain, and extreme fatigue.
Document the instruction and the follow-up plan. Do not tell him to stop metformin permanently; the hold is temporary and depends on the 48-hour renal function check. Coordinate with the referring clinician so that the follow-up eGFR is actually ordered.
3. How would you explain the risk to the patient and document the encounter?
Read the worked answer
Explain in plain language: 'The specific dye your doctor requested is not recommended for your kidney function. If we need contrast, we would use a different agent and only at the lowest dose, after the radiologist reviews the benefit and risk. We may also be able to answer the question without contrast.' Acknowledge his father's dialysis history and ask what he understands about his own kidney function. Avoid promising that any gadolinium is completely risk-free.
Document:
- The eGFR value, date, and source.
- That gadoxetate was requested but not given because of the contraindication.
- The radiologist's risk-benefit decision and the agent and dose if used.
- The metformin hold and 48-hour renal-function plan.
- The patient's questions and informed consent or refusal.
- Notification of the referring clinician about the change from the original request.
If the study is performed without contrast, state that in the report request so the radiologist interprets it as a non-contrast study rather than an incomplete contrast study.